

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2019

Reference is made to the annual report of China Biotech Services Holdings Limited (“**Company**”, together with its subsidiaries, the “**Group**”) dated 24 March 2020 (“**2019 Annual Report**”) in respect of the annual results of the Group for the year ended 31 December 2019. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the 2019 Annual Report.

Further to the information disclosed in the 2019 Annual Report, the Company would like to provide the shareholders of the Company and potential investors with the following additional information about the performance of the Group’s significant investments:

SIGNIFICANT INVESTMENTS HELD AND PERFORMANCE

Financial assets at fair value through other comprehensive income

Description of investments	Fair value of investments as at 31 December 2019 HK\$’000	Initial investment costs HK\$’000	Fair value relative to the total assets of the Group as at 31 December 2019
Broncus	39,307	39,282 (equivalent to US\$5,000,001.54)	9.44%
Pillar	38,880	39,207 (equivalent to US\$4,999,999)	9.33%

GENERAL

The above additional information does not affect other information contained in the 2019 Annual Report and, save as disclosed in this announcement, the contents of the 2019 Annual Report remain correct and unchanged.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Co-Chairman and Executive Director

Hong Kong, 31 July 2020

As at the date of this announcement, the board of Directors comprises six executive Directors, namely, Mr. Liu Xiaolin (Co-Chairman), Mr. Yao Michael Yi (Co-Chairman), Mr. He Xun, Mr. Huang Song, Mr. Leung Pak Hou Anson and Mr. Wang Zheng; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.